
A panel Monday at the 2021 American Heart Association Scientific Sessions featured new results for several heart failure (HF) therapeutics, including finerenone and empagliflozin, as well as cost-effectiveness data for vericiguat.

A panel Monday at the 2021 American Heart Association Scientific Sessions featured new results for several heart failure (HF) therapeutics, including finerenone and empagliflozin, as well as cost-effectiveness data for vericiguat.

The VICTORIA study found vericiguat to be more cost-effective than placebo when using current societal benchmarks for health care value in the United States. Derek Chew, MD, now an assistant professor at the University of Calgary, conducted economic evaluations for the VICTORIA trial while with the Duke Clinical Research Institute. Results were presented at the 2021 AHA Scientific Sessions. Here, he explains why vericiguat is more cost-effective for patients with heart failure with reduced ejection fraction.

Posters presented at the American Academy of Ophthalmology 2021 annual meeting showed that even patients with mild inflammation with their thyroid eye disease benefitted from teprotumumab and that real-world adherence was consistent with the pivotal clinical trials.

Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the latest in enhanced monofocal intraocular lenses (IOLs).

David Ramsey, MD, PhD, MPH, explains findings from a study on telehealth use among patients with diabetes in Massachusetts.

A wide-ranging discussion sought to bring greater urgency to achieving health equity during the 2021 American Heart Association (AHA) Scientific Sessions.

Ian J. Neeland, MD, FACC, FAHA, is co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute and director of the UH Center for Cardiovascular Prevention, in the Cleveland, Ohio, area. He summarized a talk he gave at the 2021 AHA Scientific Sessions, “Disrupted Sleep in Diabetic Vascular Complications."

James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, outlines the benefits and challenges of transferring ophthalmic care to outpatient facilities.

At the 2021 AHA Scientific Sessions, the lead author of DREAM-HF said evidence of the treatment's benefit among patients with elevated inflammation is positive news, and shows a need for further study.

Despite ample trial evidence that empagliflozin is effective across a broad spectrum of chronic heart failure, some doctors had been reluctant to prescribe in an acute hospital setting for safety reasons. EMPULSE findings presented at the 2021 AHA Scientific Sessions address this concern.

Michael Dorsch, PharmD, MS, describes just-in-time adaptive interventions and microrandomized trials in mHealth, which he discussed at the 2021 American Heart Association Scientific Sessions.

Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center discusses patient feedback on Tepezza (teprotumumab) for thyroid eye disease.

The field of ophthalmology had already been moving toward telehealth and artificial intelligence (AI) before the COVID-19 pandemic, but these changes are being accelerated now, making it crucial for ophthalmologists to learn to adapt.

Leon Herndon Jr, MD, a glaucoma specialist, ophthalmologist, and professor of ophthalmology at the Duke University Eye Center, discusses how a patient’s age can affect their glaucoma symptoms and treatment.

A session at the American Heart Association Scientific Sessions covered the data behind concerns about mRNA vaccines for COVID-19 and myocarditis. Then, leaders from Pfizer and Moderna discussed opportunities the technology offers.

Aaron Lee, MD, an associate professor of ophthalmology at University of Washington, describes how artificial intelligence (AI) is used in ophthalmology now and how it could be utilized in the future.

Emergency department utilization for nonemergent ophthalmic conditions is on the rise in the United States, but presentation types vary significantly based on patient demographics, according to 2 posters presented at the American Academy of Ophthalmology (AAO) 2021 meeting.

Victoria Ly, MD, MPH, explains the results of her study on follow-up among students in Arkansas who failed their vision screening tests.

Judith Lavrich, MD, and Jordan Hamburger outline findings from their research on virtual school and children's eye health.

Certain ophthalmic subspecialties were more well suited for telemedicine use based on what tends to get covered in patient visits, said Darren Chen, MD student at Weill Cornell Graduate School of Medical Sciences.

The real-world visual acuity gains in age-related macular degeneration (AMD) after treatment have been inferior to those seen in clinical trials, explained a speaker during the American Academy of Ophthalmology 2021 meeting.

Most of the adverse events that resulted from use of teprotumumab have been reversible, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.

Data about prescribing preferences and protective effects of GLP-1 receptor agonists in diabetes were presented on the opening day of the 2021 American Heart Association Scientific Sessions, held in a virtual format.

Clyde W. Yancy, MD, MSc, of Northwestern University’s Feinberg School of Medicine, explains the connections between health care equity and advances in treatment for heart failure and how the United States' policy and science agenda can address them.

Khadijah Breathett, MD, MS, FACC, FAHA, FHFSA, is an assistant professor in the University of Arizona College of Medicine--Tucson, Division of Cardiology. She is presenting a talk at the American Heart Association (AHA) Scientific Sessions, "COVID-19 as a Catalyst to Address Disparities in Cardiovascular Outcomes and Inequities in Cardiovascular Care Delivery.”

Patients with thyroid eye disease (TED) have high rates of health care resource utilization (HRU) and their disease has substantial impact on their quality of life (QOL).

Experts presenting at the American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Fall Scientific Symposium outlined racial/ethnic disparities in ocular complications.

Unlike other options in the past, teprotumumab actually addresses bulging eye and double vision associated with thyroid eye disease (TED), which patients primarily care about, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Whether or not a child’s vision is impacted by ptosis, there are usually alternatives to surgery, which is elective, said William Katowitz, MD, attending surgeon in the Division of Ophthalmology at Children's Hospital of Philadelphia.

Studies presented at the American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Fall Scientific Symposium explored the impact of lower dose rituximab on orbital lymphoma and factors associated with survival in conjunctival lymphoma.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
